Vous avez cherché: transdermalnega (Slovène - Anglais)

po odstranitvi transdermalnega obliža
after removing the transdermal patch

transdermalnega obliža ne odplaknite v stranišče.
the transdermal patch should not be flushed down the toilet.

ne nosite transdermalnega obliža v vodi dalj časa.
try to avoid wearing the transdermal patch in water for long periods of time.

ne hranite transdermalnega obliža zunaj zataljene vrečice.
do not keep or store the transdermal patch outside the sealed sachet.

lepilo transdermalnega obliža: akrilno-vinilacetatni kopolimer
transdermal patch adhesive: acrylate-vinylacetate copolymer

po tem z uporabo transdermalnega obliža evra nadaljuje kot običajno.
following this, the regular application of evra is resumed.

stanje dinamičnega ravnovesja je doseženo pri drugi aplikaciji transdermalnega obliža.
steady-state conditions are reached during the second application of the transdermal patch.

preob utljivost na u inkovino ali druge pomožne snovi transdermalnega obliža.
hypersensitivity to the active substance or to any other excipients of the transdermal patch.

mesto uporabe naj bo pokrito še nadaljnjih 10 dni po odstranitvi transdermalnega obliža.
continue to keep the application site covered for a further 10 days after removing the transdermal patch.

lepljiva stran transdermalnega obliža je pokrita s čvrsto plastično podlogo iz dveh delov.
the sticky side of the transdermal patch is covered by a two-piece rigid plastic film.

transdermalnega obliža ne smemo namestiti na kožo, ki je rdeča, vneta ali poškodovana.
the transdermal patch should not be placed on skin that is red, irritated or damaged.

koncentracija oksibutinina v plazmi pade v 1 do 2 urah po odstranitvi transdermalnega sistema / sistemov.
plasma concentration of oxybutynin declines within 1 to 2 hours after removal of transdermal system(s).

iz 1 transdermalnega obliža se sprostijo 203 mikrogrami norelgestromina in 33,9 mikrogramov etinilestradiola v 24 urah.
1 patch releases: 203 micrograms norelgestromin and 33.9 micrograms ethinyl estradiol per 24 hours

na voljo je v obliki transdermalnega obliža (obliža, ki dovaja zdravilo prek kože).
it is available as a transdermal patch (a patch that delivers a medicine across the skin).

po namestitvi transdermalnega obliža sancuso se granisetron absorbira počasi, največje koncentracije se dosežejo med 24 in 48 urami.
following sancuso application, granisetron is absorbed slowly, with maximal concentrations reached between 24 and 48 hours.

da bi kar najbolj zmanjšali možnost draženja kože, se transdermalnega obliža ne sme ponovno namestiti na isti predel kože v roku 14 dni.
reapplication to the exact same skin location within 14 days should be avoided to minimise the potential risk of skin irritation.

prehod z drugega kombiniranega hormonskega kontraceptiva (kombiniranih kontracepcijskih tabletk, vaginalnega obročka ali transdermalnega obliža)
when changing from another combined hormonal contraceptive (combined pill, vaginal ring, or transdermal patch)

na stegno ali na trebuh transdermalnega obliža ni priporočljivo nameščati, ker so opazili zmanjšano biološko uporabnost rivastigmina v primerih namestitve na te predele.
it is not recommended to apply the transdermal patch to the thigh or to the abdomen due to decreased bioavailability of rivastigmine observed when the transdermal patch is applied to these areas of the body.

vendar pa se ti dogodki niso pojavljali pogosteje pri uporabi transdermalnega obliža z rivastigminom 13,3 mg/24 h v primerjavi s placebom.
however, these events did not occur at a higher frequency with rivastigmine 13.3 mg/24 h transdermal patches than with placebo.

bolnike in njihove negovalce je treba opozoriti na pomembne napotke za uporabo transdermalnega obliža exelon (glejte poglavje 4.2).
patients and their caregivers must be instructed on important administration instructions for exelon transdermal patch (see section 4.2).